Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68788-8609

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68788-8609). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar chart titled 'Figure 1' comparing percentage values for two studies labeled Study 1 (YMRS) and Study 2 (MRS). Each study shows two bars: one for PBO (placebo) and one for DVPX (divalproex sodium). Study 1 shows 26% for PBO and 60% for DVPX. Study 2 shows 29% for PBO and 58% for DVPX. The percentages for DVPX are marked with an asterisk.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A line graph titled Figure 2 displays the percentage reduction in CPS rate on the vertical axis against the percentage of patients on the horizontal axis. It compares two treatments: DVPX (solid line) and Placebo (dashed line). The graph indicates improvement and worsening on the vertical axis with no change at zero percent reduction, illustrating patient response distribution for each treatment group.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A line graph titled Figure 3 showing percent reduction in CPS rate versus percent of patients for Divalproex Sodium. The graph compares two lines representing High Dose and Low Dose, with an improvement-worsening scale on the vertical axis and patient percentage on the horizontal axis.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' showing migraine rates for Placebo and Divalproex Sodium (DVPX) groups in two studies. The y-axis measures migraine rates from 0 to 6. Study 1 shows a higher rate for Placebo compared to DVPX, and Study 2 shows similar trends with lower migraine rates for DVPX than Placebo.*

FDA Label Image

Divalproex Sodium Dr 250mg (Spl Divalproex Label 250mg)

Label for Divalproex Sodium DR 250 mg delayed release tablets, generic for Depakote DR, manufactured by Sun Pharmaceutical Industries Ltd. The label includes dosage instructions in English and Spanish, federal caution warning, storage information, and a barcode. The labeler is Preferred Pharmaceuticals Inc.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of Divalproex Sodium, showing the molecular arrangement with sodium ion and organic moieties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.